Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investor Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
Investors and interested parties can access the live webcast of the fireside chat through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the website for 90 days following the event, providing an opportunity for those unable to attend the live session to catch up on the discussion.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q2 2024 financial results and business highlights. The company is actively enrolling subjects in ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease. In July 2024, Acumen dosed the first subject in a Phase 1 study for subcutaneous administration of sabirnetug, with topline results expected in Q1 2025. The company's cash position of $281.4 million as of June 30, 2024, is expected to support operations into H1 2027.
Financial highlights include:
- R&D expenses increased to $19.5 million in Q2 2024 from $9.1 million in Q2 2023
- G&A expenses rose to $4.8 million in Q2 2024 from $4.3 million in Q2 2023
- Net loss widened to $20.5 million in Q2 2024 from $11.6 million in Q2 2023
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic for Alzheimer's disease, has announced its plans to report second quarter 2024 financial results on August 13, 2024. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Interested parties can register for the live conference call using a provided link, which will furnish dial-in numbers and a PIN. Registration should be completed at least one day in advance. An archived version of the webcast will be available for a minimum of 30 days in the Investors section of Acumen's website.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced the dosing of the first subject in a Phase 1 study of subcutaneous sabirnetug (ACU193) for early Alzheimer's disease. The study aims to compare the pharmacokinetics between subcutaneous and intravenous administrations in healthy volunteers. Sabirnetug, co-formulated with Halozyme's ENHANZE® technology, targets soluble amyloid beta oligomers (AβOs) in the brain.
The subcutaneous formulation is designed to provide a more convenient and accessible option for patients, potentially improving treatment adherence. Acumen is also currently conducting the ALTITUDE-AD Phase 2 trial to evaluate the efficacy and safety of intravenous sabirnetug in early AD patients. Previous Phase 1 results showed favorable safety, target engagement, and amyloid plaque reduction comparable to approved therapies.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024. The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring sabirnetug in cerebrospinal fluid. Sabirnetug, a humanized monoclonal antibody, targets toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD).
Key findings include:
- Patient interviews revealed desires for treatments that slow disease progression and maintain cognitive abilities
- Sabirnetug significantly lowered CSF levels of synaptic proteins, supporting its mechanism of action
- A new ultra-sensitive assay was developed to detect sabirnetug in CSF
Acumen is currently conducting the Phase 2 ALTITUDE-AD trial to further evaluate sabirnetug's efficacy and safety in early AD patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online from July 28 to August 1, 2024. Sabirnetug, a humanized monoclonal antibody, has shown selective target engagement of toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD) patients. The company’s posters will discuss biomarker data, methods for detecting sabirnetug levels in cerebrospinal fluid (CSF), and patient experiences. The data aims to inform future clinical trials and potentially position sabirnetug as a best-in-class antibody treatment for early symptomatic AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2024 financial results and business highlights. The company announced the initiation of ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease, with the first patient dosed in May 2024. A Phase 1 study for a subcutaneous form of sabirnetug is expected in mid-2024. As of March 31, 2024, Acumen had $296.6 million in cash and equivalents, projected to fund operations into H1 2027. Financial results showed a net loss of $14.9 million, up from $11.3 million YoY. R&D expenses rose to $12.4 million from $8.7 million, while G&A expenses increased to $5.3 million from $4.4 million.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company focuses on developing therapeutics targeting toxic soluble amyloid beta oligomers for treating Alzheimer's disease. The management will join a fireside chat scheduled for May 20, 2024, at 12:30 p.m. ET. The event will be available via a live webcast on the company's investor relations page, with an archive accessible for 90 days.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in the 2024 Bank of America Healthcare Conference to discuss their novel therapeutic for treating Alzheimer's disease. The event will take place on May 15, 2024, and can be accessed via a live webcast on their website.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has started the ALTITUDE-AD Phase 2 clinical trial of sabirnetug (ACU193) in early Alzheimer's Disease, representing a significant development in Alzheimer's research. This trial aims to evaluate the efficacy and safety of sabirnetug in patients with early AD, with promising Phase 1 results supporting its mechanism of action. The study will enroll approximately 540 patients with early AD and assess primary and secondary endpoints over 18 months.